Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
Kim Linton(The Christie NHS Foundation Trust), Catherine Thiéblemont(Université Paris Cité), Michael Roost Clausen(Vejle Sygehus), Martine E.D. Chamuleau(Hovon), Diana Gernhardt(Genmab (United States)), Brian Hess(Washington University in St. Louis), Elena Favaro(Genmab (Denmark)), Tara Cochrane(Gold Coast Hospital), Sirpa Leppä(University of Helsinki), Martin Hutchings(University of Copenhagen), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Rebekah Conlon(AbbVie (United States)), Raúl Córdoba(Hospital Universitario Fundación Jiménez Díaz), Emmanuel Gyan(Inserm), Craig Okada(Oregon Health & Science University), Anna Maria Sureda Balari(Institut d'Investigació Biomédica de Bellvitge), Yan Liu(Genmab (United States)), Wojciech Jurczak(Jagiellonian University), David Lewis(University Hospitals Plymouth NHS Trust), Jacob Haaber Christensen(Odense University Hospital), Umberto Vitolo(Candiolo Cancer Institute), Işıl Altıntaş(Genmab (Netherlands)), Hervé Tilly(Centre Virchow-Villermé)
Cited by 38
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523